Physician profile
Meghan E Corkery
NPI 1053763557
$1,783.15
in general payments reported to CMS, 2019-2025
15 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Vision Therapy provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $17.51 · 2021: $263 · 2022: $314 · 2023: $248 · 2024: $225 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $353.12 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $323.77 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $227.29 | 2022-2025 | Xiidra, Miebo, Infuse |
| Alcon Vision LLC | $183.51 | 2021-2025 | Rocklatan |
| Rxsight INC | $136.42 | 2023 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Coopervision INC. | $132.55 | 2021-2023 | Myday Contact Lens |
| Novartis Pharmaceuticals Corporation | $108.62 | 2021-2023 | |
| Ocular Therapeutix, INC. | $99.55 | 2025 | |
| Harrow Eye, LLC | $56.42 | 2025 | Vevye |
| Kala Pharmaceuticals, INC. | $37.30 | 2021 | |
| Abbvie INC. | $32.54 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $25.57 | 2024 | Xdemvy |
| Oyster Point Pharma, INC. | $23.68 | 2023 | Tyrvaya |
| Biotissue Holdings INC. | $23.25 | 2025 | |
| Dompe US, INC. | $19.56 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Corkery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.